Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: A population-based case-control study

Cancer

Volumn 118, Issue 19, 2012, Pages 4768-4776

  Johannesdottir, Sigrun Alba ^a   Chang, Ellen T ^b,c   Mehnert, Frank ^a   Schmidt, Morten ^a   Olesen, Anne Braae ^a   Saørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

case control study; chemoprevention; epidemiology; nonsteroidal anti inflammatory drugs; skin neoplasm

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; DENMARK; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COMORBIDITY; CYCLOOXYGENASE INHIBITORS; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; ODDS RATIO; SKIN NEOPLASMS;

EID: 84866488761     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27406     Document Type: Article

References (41)

1. Baron JA,. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003; 37: 1-24.
2. Asgari M, White E, Chren MM,. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol Surg. 2004; 30: 1335-1342.
3. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC,. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol. 2005; 53: 966-972.
4. Asgari MM, Chren MM, Warton EM, Friedman GD, White E,. Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol. 2010; 146: 388-395.
5. Asgari MM, Maruti SS, White E,. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst. 2008; 100: 967-971.
6. Clouser MC, Roe DJ, Foote JA, Harris RB,. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf. 2009; 18: 276-283.
7. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS,. Long-Term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011; 131: 1460-1468.
8. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010; 102: 1835-1844.
9. Ramirez CC, Ma F, Federman DG, Kirsner RS,. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg. 2005; 31: 748-752.
10. Joosse A, Koomen ER, Casparie MK, Herings RMC, Guchelaar H-J, Nijsten T,. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol. 2009; 129: 2620-2627.
11. Harris RE, Beebe-Donk J, Namboodiri KK,. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep. 2001; 8: 655-657.
12. Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer. 2006; 119: 682-686.
13. Torti DC, Christensen BC, Storm CA, et al. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol. 2011; 65: 304-312.
14. Ehrenstein V, Antonsen S, Pedersen L,. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol. 2010; 2: 273-279.
15. Danish Medicines Agency. Information on over-The-counter medicine and reimbursement criteria in Denmark. Available from: http://www.dkma.dk. Accessed January 20, 2011.
16. Pedersen CB,. The Danish civil registration system. Scand J Public Health. 2011; 39: 22-25.
17. Storm HH, Michelsen EV, Clemmensen IH, Pihl J,. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull. 1997; 44: 535-539.
18. Madan V, Lear JT, Szeimies RM,. Non-melanoma skin cancer. Lancet. 2010; 375: 673-685.
19. Thompson J, Scolyer R, Kefford R,. Cutaneous melanoma. Lancet. 2005; 365: 687-701.
20. Pearce N,. What does the odds ratio estimate in a case-control study? Int J Epidemiol. 1993; 22: 1189-1192.
21. Capone ML, Tacconelli S, Difrancesco L, Sacchetti A, Sciulli MG, Patrignani P,. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007; 82: 85-94.
22. Mellemkjaer L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol. 2002; 53: 173-181.
23. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH,. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999; 46: 263-268.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
25. Drug, package sizes, and indications for use on the Danish drug market, Danish Drug Information (Dansk Lægemiddel Information A/S). Available from: http://www.lmk.dk. Accessed 20 May 2011.
26. Lanoy E, Engels EA,. Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer. 2010; 103: 112-114.
27. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH,. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996; 32A: 1753-1757.
28. Frentz G, Olsen JH,. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol. 1999; 140: 237-242.
29. Jensen AO, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer. 2008; 100: 200-205.
30. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR,. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer. 2008; 99: 1522-1528.
31. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet. 1991; 338: 91-93.
32. Litt JZ,. Drug Eruption Reference Manual. 17th ed. London, United Kingdom: Informa Healthcare; 2011.
33. Furstenberger G, Marks F, Muller-Decker K,. Cyclooxygenase-2 and skin carcinogenesis. Prog Exp Tumor Res. 2003; 37: 72-89.
34. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol. 2002; 76: 73-80.
35. Cahoon E, Rajaraman P, Alexander B, Doody M, Linet M, Freedman D,. Use of non-steroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists Study [published online ahead of print July 21, 2011]. Int J Cancer. 2011.
36. Frentz G,. General skin cancer. Quantity, treatment and quality. Ugeskr Laeger. 1996; 158: 7202.
37. Klit A, Drejoe JB, Drzewiecki KT,. Trends in the incidence of malignant melanoma in Denmark 1978-2007. Incidence on the island of Bornholm compared with the whole country incidence in Denmark. Dan Med Bull. 2011; 58: 1-4.
38. Hargreave M, Andersen TV, Nielsen A, Munk C, Liaw KL, Kjaer SK,. Factors associated with a continuous regular analgesic use-a population-based study of more than 45,000 Danish women and men 18-45 years of age. Pharmacoepidemiol Drug Saf. 2010; 19: 65-74.
39. Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M,. Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol. 2003; 192: 294-306.
40. Vad NM, Kudugunti SK, Graber D, Bailey N, Srivenugopal K, Moridani MY,. Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. Int J Oncol. 2009; 35: 193-204.
41. Friis S, Nielsen GL, Mellemkjaer L, et al. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer. 2002; 97: 96-101.